CASI director reports vested option holdings

CASI Pharmaceuticals director Barbara Helene Hannelore Krebs-Pohl filed an initial Form 3 reporting existing stock option holdings.

Accepted by SEC EDGAR 03/27/2026 - 08:19 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

CASI Pharmaceuticals director Barbara Helene Hannelore Krebs-Pohl filed an initial Form 3 reporting existing stock option holdings. She holds two fully vested options, each covering 10,000 ordinary shares, with exercise prices of $6.41 and $2.31 per share and expirations in 2034 and 2035, all owned directly. The footnote states these options are fully vested and exercisable as of the Form 3 date, and no buy or sell transactions are reported.

Insider Trade Summary

Holdings reported, no transactions

Holdings

Insider Krebs-Pohl Barbara Helene Hannelore

Role Director

Type	Security	Shares	Price	Value
Holding	Option (right to buy)	--	--	--
Holding	Option (right to buy)	--	--	--

Holdings: Option (right to buy) — 20,000 contracts (Direct)

Footnotes (1)

1. F1. The options are fully vested and exercisable as of the date of this form.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the CASI (CASI) Form 3 filing by Barbara Krebs-Pohl show?

The Form 3 shows Barbara Helene Hannelore Krebs-Pohl’s existing holdings of two stock option awards, each for 10,000 CASI ordinary shares, which are fully vested and exercisable and held directly, with exercise prices of $6.41 and $2.31 per share.

Did the CASI (CASI) Form 3 report any share purchases or sales?

No, the Form 3 does not report any share purchases or sales. It only lists existing, fully vested stock options representing 10,000 underlying shares each, disclosing Krebs-Pohl’s derivative positions rather than new trading activity in CASI stock.

What stock options does Barbara Krebs-Pohl hold in CASI (CASI)?

She holds two direct option positions, each covering 10,000 underlying ordinary shares of CASI. One has a $6.41 exercise price expiring in 2034, and the other has a $2.31 exercise price expiring in 2035, both fully vested and exercisable.

Are the CASI (CASI) options held by Barbara Krebs-Pohl fully vested?

Yes, the footnote states the options are fully vested and exercisable as of the Form 3 date. This means Krebs-Pohl can exercise each option for 10,000 ordinary shares at the stated exercise prices, subject to their future expiration dates.

Is Krebs-Pohl’s ownership in CASI (CASI) direct or through another entity?

The Form 3 labels her ownership as direct for both option positions. There are no footnotes indicating that the options are held through a trust, LLC, or other related entity, so the reported derivative holdings are attributed directly to her.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Krebs-Pohl Barbara Helene Hannelore

(Last) (First) (Middle)

MUEHLTHALER STR 106

(Street)

MUNICH 81475

(City) (State) (Zip)

GERMANY

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
CASI Pharmaceuticals, Inc. [ CASIF ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option (right to buy)	(1)	09/01/2034	Ordinary Share	10,000	$6.41	D
Option (right to buy)	(1)	09/02/2035	Ordinary Share	10,000	$2.31	D

Explanation of Responses:

1. The options are fully vested and exercisable as of the date of this form.

	/s/ Barbara Krebs-Pohl	03/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)